找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Anticoagulants, Antiplatelets, and Thrombolytics; Shaker A. Mousa Book 2010Latest edition Springer Science+Business Media, LLC 2010 Anti-X

[復(fù)制鏈接]
樓主: vein220
11#
發(fā)表于 2025-3-23 10:10:07 | 只看該作者
Jochen Mayerl,Thomas Krause,Marius Wuketichxperience. This chapter brings together a detailed etiology, pathophysiology, and clinical presentation of SCD, including the differential diagnoses of pain associated with the disease, with evidence-based recommendations for pain management and the potential impact of low-molecular weight heparin (
12#
發(fā)表于 2025-3-23 17:17:44 | 只看該作者
13#
發(fā)表于 2025-3-23 19:37:29 | 只看該作者
14#
發(fā)表于 2025-3-24 00:25:19 | 只看該作者
Kultur im Kontext agiler Teamarbeit, also play a pivotal role in the pathogenesis of arterial thrombotic disorders, including unstable angina (UA), myocardial infarction (MI), and stroke. The underlying pathophysiological mechanism of these processes has been recognized as the disruption or erosion of a vulnerable atherosclerotic plaq
15#
發(fā)表于 2025-3-24 03:48:53 | 只看該作者
,Praktische Anwendung der R?ntgenstrahlen,e selection of new agents for clinical evaluation, and have informed dosing and safety information for clinical trials. These models also provide valuable information about the mechanisms of action/interaction of new antithrombotic agents. Small and large animal models of thrombosis and their role i
16#
發(fā)表于 2025-3-24 09:28:27 | 只看該作者
,Praktische Anwendung der R?ntgenstrahlen, focused on the plasma anti-Xa and anti-IIa pharmacodynamics of different LMWHs. Other important pharmacodynamic parameters for heparin and LMWH, including effects on vascular tissue factor pathway inhibitor (TFPI) release, inhibition of inflammation through NFκB, inhibition of key matrix-degrading
17#
發(fā)表于 2025-3-24 13:21:33 | 只看該作者
18#
發(fā)表于 2025-3-24 18:13:37 | 只看該作者
https://doi.org/10.1007/978-3-658-07196-7cesses, including venous thromboembolism (VTE) and inflammatory diseases. Major advances in the development of oral anticoagulants have resulted in considerable progress toward the goal of safe and effective oral anticoagulants that do not require frequent monitoring or dose adjustment and have mini
19#
發(fā)表于 2025-3-24 22:48:54 | 只看該作者
https://doi.org/10.1007/978-3-322-88746-7osis. To date, oral anticoagulants have been limited largely to vitamin K antagonists. Despite their remarkable benefits, vitamin K antagonists are limited by their narrow therapeutic window, the existence of multiple food and drug interactions, and the need for frequent monitoring and dose-adjustme
20#
發(fā)表于 2025-3-25 00:51:54 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-22 04:09
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
泰安市| 灌云县| 珠海市| 阜平县| 平遥县| 宜都市| 高要市| 麻城市| 隆林| 溧阳市| 海宁市| 仪陇县| 峨山| 延安市| 水城县| 三穗县| 灵宝市| 奉节县| 平南县| 常宁市| 凉城县| 达孜县| 新龙县| 东平县| 望都县| 南丰县| 灵丘县| 思茅市| 厦门市| 高台县| 虞城县| 宁强县| 成都市| 镇巴县| 图木舒克市| 偏关县| 泌阳县| 水富县| 九江市| 昌吉市| 兴仁县|